Archimedes Pharma announces major fundraising of GBP 65 million

Appoints new Chief Executive Officer to accelerate growth of transatlantic business

Reading, UK, 2 March 2010

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised £65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

Click here to read Archimedes' press release.